Liquidity ratios measure the company ability to meet its short-term obligations.
Paying user area
Try for free
Thermo Fisher Scientific Inc. pages available for free this week:
- Income Statement
- Statement of Comprehensive Income
- Balance Sheet: Assets
- Common-Size Balance Sheet: Assets
- Analysis of Profitability Ratios
- Net Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Current Ratio since 2005
- Price to Operating Profit (P/OP) since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Thermo Fisher Scientific Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Liquidity Ratios (Summary)
Based on: 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-26), 10-Q (reporting date: 2020-06-27), 10-Q (reporting date: 2020-03-28).
- Current Ratio
- The current ratio demonstrates notable fluctuations over the examined periods. Initially, there is an upward trend from 2.32 in March 2020 to a peak of 3.19 in October 2021, indicating improving short-term liquidity during this timeframe. Following this peak, a sharp decline occurs in December 2021, dropping to 1.5, which suggests a sudden decrease in the company’s ability to cover short-term liabilities with current assets. Thereafter, the ratio stabilizes somewhat, fluctuating modestly between approximately 1.27 and 1.77 through to March 2025, signaling relatively stable but lower liquidity compared to the earlier period.
- Quick Ratio
- The quick ratio follows a somewhat parallel pattern to the current ratio but at lower absolute values, reflecting a more conservative measure excluding inventory. It rises steadily from 1.48 in March 2020 to a peak of 2.37 in October 2021, highlighting enhanced immediate liquidity. Subsequently, a steep decline occurs by December 2021 to a value of 1, representing reduced liquid asset coverage for current liabilities. Over the following years, the ratio settles between approximately 0.8 and 1.27, which points to a moderate capacity to meet short-term obligations without reliance on inventory.
- Cash Ratio
- The cash ratio exhibits the most volatility and generally lower levels compared to the other liquidity ratios. It increases from 0.54 in March 2020 to a peak of 1.55 in October 2021, indicating a peak in available cash and cash equivalents relative to current liabilities. However, a sharp decline follows to 0.33 by December 2021, with even lower troughs in mid-to-late 2022 around 0.17 to 0.26, suggesting a relative decrease in immediately available cash. From 2023 onwards, the cash ratio fluctuates between approximately 0.22 and 0.6, demonstrating a cautious liquidity position with limited cash reserves on hand compared to liabilities.
Current Ratio
Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | Dec 31, 2021 | Oct 2, 2021 | Jul 3, 2021 | Apr 3, 2021 | Dec 31, 2020 | Sep 26, 2020 | Jun 27, 2020 | Mar 28, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Current assets | ||||||||||||||||||||||||||||
Current liabilities | ||||||||||||||||||||||||||||
Liquidity Ratio | ||||||||||||||||||||||||||||
Current ratio1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Current Ratio, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-26), 10-Q (reporting date: 2020-06-27), 10-Q (reporting date: 2020-03-28).
1 Q1 2025 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The analyzed quarterly financial data indicates variability in both current assets and current liabilities over the observed periods, affecting the company's liquidity as reflected in the current ratio.
- Current Assets Trend
- Current assets show a general upward trajectory from March 2020 through the end of 2020, increasing significantly from 12,738 million USD to 21,957 million USD. After reaching this high, a visible decline occurs during the early part of 2021, followed by fluctuations rising and falling across subsequent quarters. Peaks appear notably around October 2021 (24,724 million USD) and December 2022 (25,229 million USD). The figures continue to oscillate in 2023 and the first quarter of 2024, with a peak at around 25,476 million USD in June 2024, before experiencing a moderate decrease again towards March 2025.
- Current Liabilities Trend
- Current liabilities demonstrate a considerable increase during 2020, particularly surging in the fourth quarter to 10,304 million USD from a prior range of roughly 5,500 to 6,228 million USD. Subsequently, liabilities exhibit a pattern of rising and falling, with elevated values persisting in the later quarters of 2021 through 2024. The peak liability occurs again in December 2022 at 17,010 million USD. Post this peak, a gradual decline is noted through early 2025, ending at 13,174 million USD in March 2025.
- Current Ratio and Liquidity Insights
- The current ratio, a key indicator of short-term financial health, reflects the changes in assets and liabilities. It peaked at 2.93 in September 2020 but sharply decreased to 1.5 by December 2021, indicating a reduced margin of available current assets relative to liabilities. Throughout 2022 and 2023, the ratio stays below 2.0 consistently, reflecting a tighter liquidity position compared to earlier periods. It trends slightly upward from early 2023 into 2025, reaching 1.77 as of March 2025, which suggests some improvement in liquidity but still at a more conservative level relative to the earlier years. The overall trend indicates the company experienced significant liquidity compression after 2020, with partial recovery efforts evident in the most recent quarters.
Quick Ratio
Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | Dec 31, 2021 | Oct 2, 2021 | Jul 3, 2021 | Apr 3, 2021 | Dec 31, 2020 | Sep 26, 2020 | Jun 27, 2020 | Mar 28, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Cash and cash equivalents | ||||||||||||||||||||||||||||
Short-term investments | ||||||||||||||||||||||||||||
Accounts receivable, less allowances | ||||||||||||||||||||||||||||
Contract assets, net | ||||||||||||||||||||||||||||
Total quick assets | ||||||||||||||||||||||||||||
Current liabilities | ||||||||||||||||||||||||||||
Liquidity Ratio | ||||||||||||||||||||||||||||
Quick ratio1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Quick Ratio, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-26), 10-Q (reporting date: 2020-06-27), 10-Q (reporting date: 2020-03-28).
1 Q1 2025 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The quarterly financial data reveals distinct trends in the company's liquidity position over the observed periods. The focus is on total quick assets, current liabilities, and the quick ratio, which collectively provide insight into short-term financial health and the ability to cover immediate obligations without relying on inventory sales.
- Total Quick Assets
- Total quick assets showed an overall upward trend from early 2020 through 2021, increasing significantly from 8.1 billion USD in March 2020 to a peak of approximately 18.4 billion USD by October 2021. However, there was notable volatility thereafter, with values fluctuating between approximately 11.7 billion and 17.9 billion USD from late 2021 through early 2023. After this period of variation, quick assets generally trended upward again into 2024, reaching a high of roughly 18.3 billion USD in mid-2024 before a slight decline to around 15.8 billion USD by March 2025.
- Current Liabilities
- Current liabilities followed a somewhat similar but distinct pattern, starting at 5.5 billion USD in March 2020 and gradually increasing to a peak of 17.0 billion USD by December 2022. Subsequently, current liabilities began a general decline, dropping to approximately 13.2 billion USD by March 2025. This decline in current liabilities after the peak suggests improved management of short-term obligations or changes in creditor payment terms starting from late 2022 onward.
- Quick Ratio
- The quick ratio showed considerable fluctuations throughout the periods. Initially, it improved significantly from 1.48 in March 2020 to a high of 2.37 in October 2021, coinciding with rising quick assets relative to current liabilities. However, the ratio then experienced a sharp drop to approximately 1.0 in December 2021, indicating a decrease in liquidity relative to short-term liabilities. From early 2022 through 2023, the ratio hovered just above or below 1.0, suggesting a relatively balanced but tighter liquidity position. In 2023 and into 2024, the quick ratio improved gradually, rising to around 1.2 by the end of the observation period, reflecting a moderate strengthening of the company’s ability to meet short-term liabilities without relying on inventory.
Overall, the data indicates that while the company enhanced its liquid asset base substantially until late 2021, there was subsequent volatility with a tightening in liquidity measures through 2022. The management of current liabilities appeared to improve from late 2022, contributing to a gradual recovery and stabilization in the quick ratio by early 2025. These trends suggest an ongoing adjustment phase in working capital management following a period of significant buildup in quick assets during 2020 and 2021.
Cash Ratio
Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | Dec 31, 2021 | Oct 2, 2021 | Jul 3, 2021 | Apr 3, 2021 | Dec 31, 2020 | Sep 26, 2020 | Jun 27, 2020 | Mar 28, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Cash and cash equivalents | ||||||||||||||||||||||||||||
Short-term investments | ||||||||||||||||||||||||||||
Total cash assets | ||||||||||||||||||||||||||||
Current liabilities | ||||||||||||||||||||||||||||
Liquidity Ratio | ||||||||||||||||||||||||||||
Cash ratio1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Cash Ratio, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-26), 10-Q (reporting date: 2020-06-27), 10-Q (reporting date: 2020-03-28).
1 Q1 2025 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The analysis of the financial data reveals significant fluctuations in total cash assets, current liabilities, and the cash ratio over the periods reviewed.
- Total Cash Assets
- The total cash assets exhibit considerable variability across the quarters. Starting at 2,981 million US dollars in March 2020, cash assets peaked at 12,027 million US dollars in October 2021. Subsequently, there is a steep decline to 2,752 million US dollars by April 2022, followed by a resurgence reaching 8,080 million US dollars in December 2023. After peaking, the cash assets again display a downward trend, falling to 5,947 million US dollars by March 2025. This pattern indicates periods of significant cash accumulation interspersed with phases of reduction, possibly due to investment, operational needs, or financing activities.
- Current Liabilities
- Current liabilities demonstrate a general upward trend from 5,500 million US dollars in March 2020, rising sharply to 17,010 million US dollars in December 2022. After this peak, liabilities gradually decrease, reaching approximately 13,174 million US dollars by March 2025. The increase in liabilities over much of the period suggests expanding short-term obligations, which might reflect growing operational scale or increased short-term borrowing. The subsequent decrease points toward liability management or reduction of short-term debts.
- Cash Ratio
- The cash ratio, which measures the company's liquidity by comparing cash assets to current liabilities, shows marked volatility. It starts at 0.54 in March 2020 and improves to a high of 1.55 in October 2021, indicating a strong liquidity position at that point. However, the ratio sharply declines to below 0.3 in early to mid-2022, reflecting a weakened liquidity status. Post mid-2022, the cash ratio fluctuates between 0.22 and 0.6, without reaching previous highs, suggesting generally moderate to low liquidity relative to liabilities. The decreasing trend in the ratio during the latter periods indicates the company has had less cash on hand relative to its current liabilities, which could impact its short-term financial stability.
Overall, the data indicates a company managing substantial cash flow changes and increasing current liabilities over the periods. The declining liquidity ratio in recent quarters highlights potential concerns regarding the company’s ability to meet short-term obligations solely with cash assets, emphasizing the need for careful liquidity management going forward.